natgillin/translations-raw huggingface dataset:
The method of clause 4, wherein said antigen or antigenic peptide is from an organism selected from the group consisting of heartworm, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplasma phagocytophilum, Anaplasma platys, feline leukemia virus, parvovirus, influenza A strain, influenza B strain, avian influenza virus, respiratory syncytial virus, Legionella, adenovirus, rotavirus, feline immunodeficiency virus, human immunodeficiency virus, and Group A Streptococcus. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što je navedeni antigen ili antigeni peptid iz organizma kojeg se bira iz skupine koju čine srčana glista, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplazma phagocytophilum, Anaplazma platys, virus mačje leukemije, parvovirus, soj A influence, soj B influence, virus ptičje influence, respiratorni sincicijski virus, Legionella, adenovirus, rotavirus, virus mačje imunodeficijencije, virus ljudske imunodeficijencije, te skupina A streptokoka.
The method according claim 7, wherein the breakable seal comprises a weak point where the breakable seal is not as wide as the rest of the breakable seal, and wherein the breakable seal breaks at the weak point when pressure is applied to the flexible bag. 
Farmaceutska vrećica u skladu s patentnim zahtjevom 1, naznačena time, da brtva (130) nadalje sadržava slabu točku (132) koja tvori početnu točku lomljenja kada se na farmaceutsku vrećicu primijeni unaprijed određena količina tlaka.
The substrate can comprise a polymeric material, wherein the polymeric material is selected from the group consisting of polystyrene, polyvinyl chloride, polypropylene, polyethylene, polyamide, and polycarbonate. In some embodiments, the substrate comprises a porous carbon surface. 
Postupak prema zahtjevu 5, naznačen time što supstrat sadrži polimerni materijal, pri čemu polimerni materijal sadrži polistiren, polivinil klorid, polipropilen, polietilen, poliamid, polikarbonat ili bilo koju njihovu kombinaciju.
Compounds of the formula (II) can be prepared by reduction of tetrabenazine to give a dihydrotetrabenazine followed by dehydration of the dihydrotetrabenazine. 
Spojevi formule (II) se mogu pripremiti redukcijom tetrabenazina dajući dihidrotetrabenazin nakon čega slijedi dehidriranje dihidrotetrabenazina.
The collection according to claim 1, wherein said antibodies or fragments thereof comprise one or more complementarity determining regions comprising amino acid modifications that remove potential post translational modification sites. 
Zbirka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što navedena protutijela, ili njihovi funkcionalni fragmenti, sadrže jedno 1li više područja određivanja komplementarnosti koja sadrže aminokiselinske modifikacije koje uklanjaju potencijalna mjesta posttranslacijskih modifikacija.
Said secosteroid is preferably an analog of vitamin D, more preferably inecalcitol or a derivative thereof, of formula (III). 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što je navedeni sekosteroid analog vitamina D, formule (III):
The method of claim 1, wherein the concentration of erythropoietin protein contacted with the cyanate is about 2 mg/ml to about 5 mg/ml. 
Postupak prema patentnom zahtjevu 1, naznačen time što je koncentracija proteina eritropoetina koja je dovedena u kontakt sa cijanatom oko 2 mg/ml do oko 5 mg/ml.
is hydrogen or C1-6 alkyl optionally substituted by halo or hydroxyl; 
je vodik ili C1-6alkil, izborno supstituiran s halogenom ili hidroksilom;
Patent Document 6: International Publication WO2010/048586A1 
(87) Broj međunarodne objave:
A compound according to claim 1 to 11 for use in the treatment of a pathological condition or disease wherein the pathological condition or disease is ischemia, supraventricular arrhythmias, atrial fibrillation, acute renal failure, myocardial reperfusion injury, diseases due to fluid retention, allergic reactions including but not limited to rhinitis, urticaria, scleroderma, arthritis, other autoimmune diseases, inflammatory bowel disease, diabetes mellitus, obesity, Parkinson's disease, Huntington's disease, dystonias such as the restless leg syndrome, dyskinesias such as those caused by prolonged use of dopamine or neuroleptic drugs or sleep disorders, congestive heart failure, hypertension, intradialytic hypotension, dementia, anxiety disorders, and glaucoma. 
Spoj prema bilo kojem od zahtjeva 1 do 11 za primjenu u terapiji patološkog stanja ili bolesti, pri čemu je patološko stanje ili bolest: ishemija, supraventrikularna aritmija, fibrilacija atrija, akutno zatajenje bubrega, miokardijalna reperfuzijska ozljeda, bolesti uzrokovane retencijom tekućine, alergijske reakcije uključujući, ali ne ograničavajući se na rinitis, urtikarija, skleroderma, artritis, druge autoimune bolesti, upalna bolest crijeva, dijabetes melitus, pretilost, Parkinsonova bolest, Huntingtonova bolest, distonije kao što je sindrom nemirnih nogu, diskinezije kao što su one uzrokovane duljim uzimanjem dopamina ili neuroleptika ili poremećajima spavanja, kongestivno zatajenje srca, hipertenzija, intradijalitička hipotenzija, demencija, anksiozni poremećaji 1 glaukom.
The process according to any of claims 1-8, wherein after drying of the first aqueous liquid a coating having a dry weight of 0.2-25 g/m2, preferably 0.2-5 g/m2, is obtained on the front side of the base medium. 
Postupak prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što se nakon sušenja prve vodene tekućine na prednjoj strani osnovne podloge dobije prevlaka suhe težine 0.2-25 g/m2, poželjno 0.2-5 g/m2.
Figure 12 illustrates that 42-O-(D-Fructosylcarbonyl)rapamycin prolonged survival of the graft over the vehicle as did rapamycin at the 2.5 mg/kg/day dose level. 
Slika 12 prikazuje kako je 42-O(D-fruktozilkarbonil)rapamicin produljio preživljenje transplantata u odnosu na nosač, kao što je djelovao i rapamicin u dozi od 2,5 mg/kg/dan.
Locomotor activity data were analysed using Dunnett's t-test. 
Podaci lokomotornog djelovanja su analizirani korištenjem Dunnett's t-testa.
The mixture is cooled at 0 °C in an ice/salt bath. 
Smjesu se ohladi na 0*C u ledenoj/slanoj kupelji.
providing a coagulant solution; 
davanje otopine koagulanta;
the substitution of the glutamic acid residue at position 570 by a glutamine residue (E570Q) or by a conservative amino acid residue, and 
(1) zamjeni ostatka glutaminske kiseline, koji odgovara položaju 570 u sekvenci nativnog CyaA u Bordetella pertussis kako je definirano u SEQ ID NO:1, glutaminom;
alternatively, R4 and R5 are taken together with the atom to which they are bound to form 2-[1,3]dioxolanyl; or a pharmaceutically acceptable salt thereof. 
Alternativno, R* i R* su uzeti zajedno s atomom na koji su vezani da formiraju 2- [1,3] dioksolanil; ili njihovu farmaceutski prihvatljivu sol.
A method according to any one of the claims 1 to 4, characterised in that before being applied onto the cysts at least 90 wt % of said magnetic particles have a size smaller than 10 µm, preferably smaller than 5 µm, more preferably smaller than 1 µm and most preferably smaller than 0.5 µm. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time što prije primjene na ciste, barem 90 te2% magnetskih čestica ima veličinu manju od 10 Pm, poželjno manju od 5 Pm, još poželjnije manju od 1 Pmi najpoželjnije manju od 0.5 Pm.
the index n is an integer from 0 to 5; 
indeks n je cijeli broj od 0 do 5;
The polyester polymer of claim 1, wherein said phenolic stabilizer is from 200 to 300 ppm. 
Poliesterski polimer u skladu s patentnim zahtjevom 1, naznačen time što je navedeni fenolnmi stabilizator u količini od 200 do 300 ppm.
The pharmaceutical composition as claimed in Claim 4, wherein the hyaluronic acid has an average molecular weight ranging from about 500,000 to about 3,000,000 Dalton. 
Farmaceutski sastav za uporabu prema zahtjevu 4, naznačen time, da hijaluronska kiselina ima prosječnu molekularnu masu u rasponu od oko 500 000 do oko 3 000 000 Daltona.
It can be hermetically sealed or not. 
Ona može biti hermetički zatvorena ili ne biti hermetički zatvorena.
Immunostimulatory composition according to claim 2, wherein the G/C content of the coding region of the GC-stabilized RNA is increased compared with the G/C content of the coding region of the native RNA, the coded amino acid sequence of the GC-stabilized modified mRNA not being altered compared with the encoded amino acid sequence of the native modified mRNA. 
Imunostimulacijski pripravak prema zahtjevu 8, naznačen time da G/C sadržaj kodirajuće regije GC-stabilizirane RNK je povećan u usporedbi sa G/C sadržajem kodirajuće regije prirodne RNK, kodirana sekvenca aminokiseline GC-stabilizirane modificirane (m)RNK nije izmijenjen u usporedbi sa kodiranom sekvencom aminokiseline prirodne modificirane (m)RNK.
A genetically modified mouse, whose genome comprises a replacement at an endogenous mouse IL-15 locus, of a mouse genomic fragment coding for a mature mouse IL-15 polypeptide, with a human genomic segment coding for a mature human IL-15 polypeptide wherein the human IL-15 exons in said human genomic segment consist of human IL-15 protein-coding exons 3, 4, 5 and 6, to form a humanized IL-15 gene, wherein the IL-15 exons are numbered with the first coding exon as exon 1, and wherein the humanized IL-15 gene is under control of all endogenous mouse IL-15 upstream regulatory elements at the endogenous mouse IL-15 locus. 
Genetički modificirani miš, naznačen time što mu genom sadrži zamjenu u endogenom mišjem lokusu IL-15, u mišjem genomskom fragmentu koji kodira zreli mišji polipeptid IL-15, ljudskim genomskim segmentom koji kodira zreli ljudski polipeptid IL-15, gdje ljudske egzone u II-15 u navedenom ljudskom genomskom segmentu čine ljudski egzoni 3, 4, 5 1 6 koji kodiraju protein IL-15, kako bi se dobilo humanizirani gen za IL-15, gdje su egzoni u IL-15 tako obrojčani da je prvi kodirajući egzon egzon 1, te gdje je humanizirani gen za IL-15 pod kontrolom svih endogenih mišjih uzvodnih regulacijskih elemenata za IL-15 na endogenom mišjem lokusu IL-15.
The method of claim 7, wherein at least one accessory molecule is a sugar. 
Postupak sukladno patentnom zahtjevu 7, naznačeno time, da je najmanje jedna aksesorna molekla šećer.
The cells or article of manufacture for use according to claims 1 or 2, wherein said ischemia is selected from the group consisting of peripheral arterial disease (PAD) and ischemia of the central nervous system (CNS). 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s patentnim zahtjevima 1 ili 2, naznačeni time što se navedena ishemija bira iz skupine koju čine bolest perifernih arterija (PAD) 1 ishemija središnjeg živčanog sustava (CNS).
In an embodiment, the temperature of the rinse solution stream is greater than or equal to the temperature of the extraction liquid, so as to preserve the temperature of the extraction solution in the separation pool. 
Proces iz bilo kojeg od patentnih zahtjeva 7 do 8, gdje temperatura mlaza otopine za ispiranje je veća od ili jednaka temperaturi ekstrakcijske otopine.
contacting the trans-(+)-A9-tetrahydrocannabinol from step (b) with trans-(-)-A9-tetrahydrocannabinol and a non-polar organic solvent to form the first composition. 
(b) razdvajanje alkoholno-kaustične faze koja sadrži trans-(-)-A"-tetrahidrokanabinol i trans-(+)-A*- tetrahidrokanabinol od prve organske faze;
The pharmaceutical composition of any one of the preceding claims, wherein the composition is for intravenous, intra-arterial, intra-peritoneal, intramuscular, intradermal, in-tratumoral, oral, dermal, nasal, buccal, rectal, vaginal, by inhalation, or topical administration. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva namijenjen intravenoznoj, intra-arterijskoj, intraperitonalnoj, intramuskularnoj, intradermalnoj, intratumorskoj, oralnoj, dermalnoj, nazalnoj, bukalnoj, rektalnoj, vaginalnoj, inhalacijskoj ili topijskoj primjeni.
The liposome of claim 8, wherein the self-replicating RNA molecule encodes (i) a RNA dependent RNA polymerase which can transcribe RNA from the self-replicating RNA molecule and (ii) an immunogen. 
Liposom u skladu s patentnim zahtjevom 8, naznačen time što samoreplicirajuća molekula RNA kodira (i) RNA-ovisna RNA polimerazu koja može transkribirati RNA iz samoreplicirajuće molekule RNA i (ii) imunogen.
The method of item 14, further comprising a step d) of separating the proteins or suprastructure proteins, in the filtered fraction from the cellular debris and insoluble materials. 
suprastrukturnih protema, u filtnranoj frakciji iz staničnog krhotina 1 netopivih materijala ili d) pročišćavanja biljnih protema ili suprastrukturnih protema iz filtrirane frakcije.
Multi-purpose truck (100) for re-establishment of safe and practicable road conditions, after car accidents, through cleaning of the road platform, according to previous claim, characterized in that: 
Višenamjenski kamion (100) za ponovno uspostavljanje sigurnih i prohodnih uvjeta na cesti nakon automobilskih nezgoda, čišćenjem cestovne plohe, prema prethodnom patentnom zahtjevu, naznačen time, da
The pharmaceutical composition for use according to claim 9, which is a topical ophthalmic formulation for reducing intraocular pressure comprising from 0.05mg/ml to about 7mg/ml of the compound as defined in claim 1, and from 1mg/ml to about 140mg/ml of hydroxypropyl B-cyclodextrin in saline for injection. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 9, koji je topička oftalmička formulacija za snižavanje intraokularnog tlaka obuhvaća od 0.05 mg/mL do otprilike 7 mg/mL tvari kako je definirana u patentnom zahtjevu 1, 10d 1 mg/mL do otprilike 140 mg/mL hidroksipropil B-ciklodekstrina u fiziološkoj otopini za injekcije.
The hydroxyl laundry chemical injection system of claim 6, wherein the predetermined time is between about 60 seconds and about 99 seconds. The hydroxyl laundry chemical injection system of claim 6, wherein the hydroxyl gas generator is configured to generate hydroxyl gas having a concentration of hydroxyl radicals of at least 900 ppm during the predetermined time. 
Sustav za ubrizgavanje kemikalija za pranje rublja na bazi hidroksila (100) iz zahtjeva 1, naznačen time da generator hidroksil plina (3) uključuje ultraljubičastu (UV) svjetiljku konfiguriranu da emitira svjetlost s valnom duljinom između 365 nm i 385 nm, za potporu generiranju hidroksil plina s koncentracijom hidroksil radikala od barem 800 ppm.
The compound of formula (I') of claim 12 for its use according to claim 12, wherein in Formula (I'), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I) iz patentnog zahtjeva 12 za njegovu primjenu prema patentnom zahtjevu 12, gdje u formuli (I), R' je atom vodika, i R* je atom vodika; hidroksi grupa; ravna ili razgranata C,-C4 alkil grupa; ravna ili razgranata Ci-Cs alkoksi grupa; ili ravna ili razgranata C,-C3 tioalkil grupa.
Molecular weight, kDa 
Molekularna masa, kDa
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:129 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:128; 
(k) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 129i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 1285;
A treatment agent for use in the treatment of the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse, comprising N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide or a salt thereof. 
Sredstvo za liječenje namijenjeno uporabi u skladu s patentnim zahtjevom 5, naznačeno time, da je derivat benzopirana N-[7-[(metilsulfonil)amino]-4-okso-6-fenoksi-4H-1-benzopiran-3-il]formamid.
The integrated rotary mixer and disperser head (1) according to claim 1, 2 or 3, wherein each of the first shear parts of the first plurality of impeller blades (8) comprises a leading portion extending in a plane substantially perpendicular to the drive shaft (2), and a peripheral portion bent about 90 degrees inward from said leading portion. 
Integrirana rotacijska miješalica i glava raspršivača (1) prema 1., 2. ill 3. tvrdnji gdje se svaki od prvih posmičnih dijelova prvog mnoštva lopatica rotora (8) sastoji od prednjeg dijela koji se proteže u ravnini koja je značajno okomita na pogonsko vratilo (2) i perifernog dijela koji je savijen oko 90 stupnjeva prema unutra od navedenog prednjeg dijela.
The method of claim 1, wherein the at least one kosmotrope is selected from the group consisting of a,a-trehalose, glycerol, trimethylamine N-oxide, ectoine, 3-dimethylsulfoniopropionate, glucose, dextran, and D-lactose. 
Reagens prema zahtjevu 1, naznačen time da je daljnji kozmotrop odabran iz skupine koja sadrži glicerol, trimetilamin N-oksid, ektoin, 3-dimetilsulfoniopropionat, glukozu, dekstran, i D-laktozu.
A container comprising a base and a continuous side wall extending substantially perpendicular to the base with a peripheral flange formed along the upper, in use, edge of the continuous side wall, wherein the base and the continuous side wall consist essentially of polyethylene terephthalate (PET) wherein a layer of adhesive is located on an upper, in use, surface of the peripheral flange and said layer of adhesive does not extend onto the vertical, in use, surfaces of the continuous side wall and does not extend onto the base wherein the container further comprises a lidding film which may be sealed to the peripheral flange to create a sealed space between the base, continuous side wall and lidding film; and wherein the lidding film is a multi-layer film comprising a seal layer and the seal layer comprises polypropylene (PP) and/or PE. 
HR P20191497 T1 PATENTNI ZAHTJEVI Posuda koja sadrži osnovu i kontinuirani bočni zid koji se proteže značajno okomito na osnovu sa obodom formiranim duž gornje, pri upotrebi, ivice kontinuiranog bočnog zida, pri čemu se osnova i kontinuirani bočni zid u osnovi sastoje od polietilen tereftalata (PET) gdje se sloj ljepila nalazi na gornjoj, pri upotrebi, površini oboda i navedeni sloj ljepila se ne širi na vertikalne, pri upotrebi, površine kontinuiranog bočnog zida i ne širi se na osnovu gdje posuda osim toga sadrži tanki film koji može biti pričvršćen na obod kako bi se stvorio pričvršćeni prostor između osnove, kontinuiranog bočnog zida 1 tankog filma; i gdje je tanki film višeslojni film koji sadrži sloj za pričvršćivanje i sloj za pričvršćivanje sadrži polipropilen (PP) i/ili PE.
a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab' fragment according to Claim 1 and with an expression vector comprising a polynucleotide comprising a sequence that encodes the light chain of the Fab' fragment. 
stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab’ fragmenta u skladu s patentnim zahtjevom 2 i ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira laki lanac Fab’ fragmenta u skladu s patentnim zahtjevom 2, i konjugiranju Fab’ fragmenta protutijela protiv ljudskog NGF s polietilen-glikolom.
The method of claim 25, wherein therapeutically effective amount of crenolanib or a salt thereof is administered up to three times or more a day for as long as the subject is in need of treatment for the hematologic malignant proliferative disease. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove soli daje tri ili više puta dnevno sve dok je subjektu potrebno liječenje akutne mijeloične leukemije (AML).
Once a desired concentration is reached, the concentrated broth is slurried with a solvent in which the desired compound is soluble. 
Kada se postigne željena koncentracija, koncentrirani bujon se suspendira s otapalom u kojem je željeni spoj topljiv.
The wear member according to claim 1 or 2, characterized in that the working section (21) is an elongate bit. 
Potrošni dio u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je radni dio (21) izduljeni dio.
The sleeve 20 is operated via an operating fork 23 that is attached to the dispensing head 14 such that, by operation of a handle 25 by the user, it can move up and down and in this way displaces the sleeve 20 and moves the ball 22 up and down for dispensing beer from the container 3. 
Rukavac 20 je upravljan pomoću upravljačke vilice 23 koja je priključena na glavu raspršivača 14 tako da korisnik upravljanjem HR P20070526 T3 ručke 25, može pomicati gore i dolje i na taj način uklanja rukavac 20 i pomiče kuglu 22 gore i dolje kako bi pivo poteklo iz spremnika 3.
The antibody of any one of claims 1 to 7, which comprises the antigen binding portion or antigen binding site of an antibody obtainable from a clone deposited under the accession no. 
Protutijelo odabrano iz skupine koja se sastoji od (i) protutijela proizvedenog ili koje se može dobiti od klona deponiranog pod pristupnim br.
This results in the production of SCFA along the complete trajectory in the colon and a corresponding overall reduction of the pH in the colon. 
Time se cijelom dužinom debelog crijeva stvaraju SCFA i postiže odgovarajuće ukupno sniženje pH u debelom crijevu.
The method of claim 54, wherein R5 is selected from the group consisting of H, —C(═O)N(R9)2 and —CN. The method of claim 58, wherein R9 is selected from the group consisting of H and —C1-4 alkyl, alternatively, R9 is taken together to form a fused ring with the nitrogen. 
Spoj prema zahtjevu 6, naznačen time da R? je odabran iz skupine koja sadrži H, -C(=0)N(R*),, te -CN. Spoj prema zahtjevu 10, naznačen time da R? je odabran iz skupine koja sadrži H i -C1.4 alkil, alternativno, R? se uzima zajedno da tvori kondenzirani prsten s dušikom.
The process of claim 1, wherein the soaked liquid stream is filtered by nano-filtration. The process according to claim 4, wherein the at least a portion of the soaked liquid has an instantaneous flux greater than 7 L/h-m2, wherein the instantaneous flux is the flux when 72 L of a 190 L aliquot of the at least a portion of the soaked liquid have passed through a spiral nano-filter membrane conforming to the specifications that the membrane is a polyamide type thin film composite on polyester, has a magnesium sulfate rejection of greater than or equal to 98% when measured on 2000 ppm magnesium sulfate in water at 9 bar and 25° C. and having an outer diameter of 64.0 to 65.0 mm, a length of 432 mm and an inside diameter of 21 mm, the membrane having a cross-flow of 1.3-1.8 m3/h with a maximum pressure drop of 0.6 bar at 1 cP and design membrane area of 0.7 m2. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što u najmanju ruku dio namočene tekućine ima trenutni protok veći od 7 1/h-m2, gdje je trenutni protok protok kada se 72 1 alikvota od 190 1 u najmanju ruku dijela namočene tekućine propusti kroz membranu spiralnog nanofiltra, usklađenu sa specifikacijama, prema kojima je membrana tankoslojni kompozit poliamidnog tipa na poliesteru, ima odbijanje magnezijevog sulfata veće od ili jednako 98% kada se mjeri uz 2000 ppm magnezijevog sulfate u vodi, pod tlakom od 9 bar, na 25 "C, te ima vanjski promjer od 64,0 do 65,0 mm, duljinu od 432 mm, a unutarnji promjer od 21 mm, gdje membrana ima poprečni protok od 1,3-1,8 m3/h, uz maksimalan pad tlaka od 0,6 bar na 1 cP i dizajniranu površinu membrane od 0,7 m2.
In particular the matting agent is present in amounts of 1 to 10 wt. %, preferably in amounts of 2 to 7 wt. %, more preferably in amount of 3 to 5 wt. %, based on the total weight of the paint or coating. 
Uporaba prema zahtjevu 26, naznačena time da je matirajuće sredstvo prisutno u količinama od 1 do 10 tež.%, poželjno od 2 do 7 tež.%, poželjnije od 3 do 5 tež.% bazirano na mokroj boji.